RT Journal Article SR Electronic T1 Advances in target therapy in lung cancer JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 23 OP 29 DO 10.1183/09059180.00011014 VO 24 IS 135 A1 Jean-Paul Sculier A1 Thierry Berghmans A1 Anne-Pascale Meert YR 2015 UL http://err.ersjournals.com/content/24/135/23.abstract AB Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014, in the context of pre-existing data. Considered target therapies were tyrosine kinase inhibitors of active epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib and afatinib), anaplastic lymphoma kinase rearrangements (e.g. crizotinib) or angiogenesis (drugs under development), or monoclonal antibodies against vascular endothelial growth factor (e.g. bevacizumab) or epidermal growth factor receptors (e.g. cetuximab). The therapeutic project has to consider tyrosine kinase inhibitors in the case of nonsmall cell lung cancer with active epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement. However, these drugs should not be used in the absence of the targeted genetic abnormalities. Targeted therapies are modifying the therapeutic approach in NSCLC with specific oncogenic mutations http://ow.ly/HeVMZ